Efficacy of doripenem against Escherichia coli and Klebsiella pneumoniae in experimental meningitis

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 3, 2012, Pages 661-665

  Stucki, Armin ^a   Cottagnoud, Marianne ^b   Acosta, Fernando ^b   Egerman, Ueli ^c   Laeuffer, Jörg M ^d   Cottagnoud, Philippe ^e  

^a Clinic for Pneumology and Rehabilitation   (Switzerland)

^b Spital Netz Bern   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d Janssen EMA   (Switzerland)

^e Klinik Sonnenhof   (Switzerland)

Author keywords

Carbapenems; Kinetics; Rabbit meningitis

Indexed keywords

CEFEPIME; DORIPENEM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL MENINGITIS; CEREBROSPINAL FLUID; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; ESCHERICHIA COLI; EXPERIMENTAL RABBIT; KLEBSIELLA PNEUMONIAE; MENINX; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; CARBAPENEMS; CEPHALOSPORINS; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MENINGITIS, BACTERIAL; RABBITS; TREATMENT OUTCOME;

EID: 84856957474     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr482     Document Type: Article

References (21)

1. Jones RN. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). Semin Respir Crit Care Med 2003; 24: 121-34.
2. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34: 634-40.
3. Bonfiglio G, Russo G, Nicoletti G. Recent developments in carbapenems. Expert Opin Investig Drugs 2002; 11: 529-44.
4. Jones RN. In vitro evaluation of ertapenem (MK-0826), a long-acting carbapenem, tested against selected resistant strains. J Chemother 2001; 13: 363-76.
5. Wiseman LR, Wagstaff AJ, Brogden RN et al. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1995; 50: 73-101.
6. Iso Y, Irie T, Nishino Y et al. A novel 1 b-methylcarbapenem antibiotic, S-4661. Synthesis and structure-activity relationships of 2-(5-substituted pyrrolidin-3-ylthio)-1 b-methylcarbapenems. J Antibiot (Tokyo) 1996; 49: 199-209.
7. Jones RN, Huynh HK, Biedenbach DJ. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother 2004; 48: 3136-40.
8. Greer ND. Doripenem (Doribax): the newest addition to the carbapenems. Proc (Bayl Univ Med Cent) 2008; 21: 337-41.
9. Gerber CM, Cottagnoud M, Neftel KA et al. Meropenem alone and in combination with vancomycin in experimental meningitis caused by a penicillin-resistant pneumococcal strain. Eur J Clin Microbiol Infect Dis 1999; 18: 866-70.
10. Cottagnoud P, Pfister M, Cottagnoud M et al. Activities of ertapenem, a new long-acting carbapenem, against penicillin-sensitive or -resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2003; 47: 1943-7.
11. Dacey RG, Sande MA. Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives. Antimicrob Agents Chemother 1974; 6: 437-41.
12. Cottagnoud P, Acosta F, Cottagnoud M et al. Cefepime is efficacious against penicillin- and quinolone-resistant pneumococci in experimental meningitis. J Antimicrob Chemother 2002; 49: 327-30.
13. Gerber CM, Cottagnoud M, Neftel K et al. Evaluation of cefepime alone and in combination with vancomycin against penicillin-resistant pneumococci in the rabbit meningitis model and in vitro. J Antimicrob Chemother 2000; 45: 63-8.
14. Blaser J, Vergeres P, Widmer AF et al. In vivo verification of in vitro model of antibiotic treatment of device-related infection. Antimicrob Agents Chemother 1995; 39: 1134-9.
15. Louie A, Bied A, Fregeau C et al. Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. Antimicrob Agents Chemother 2010; 54: 2638-45.
16. Anderson DL. Doripenem. Drugs Today (Barc) 2006; 42: 399-404.
17. Bhavnani SM, Hammel JP, Cirincione BB et al. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother 2005; 49: 3944-7.
18. Cottagnoud P. Cellular and molecular aspects of drugs of the future: meropenem. Cell Mol Life Sci 2002; 59: 1928-33.
19. Lutsar I, McCracken GH Jr, Friedland IR. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis 1998; 27: 1117-27, quiz 1128-9.
20. Tunkel AR. Bacterial Meningitis. Philadelphia: Lippincott Williams & Wilkins, 2001.
21. Horiuchi M, Kimura M, Tokumura M et al. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with b-lactam antibiotics. Toxicology 2006; 222: 114-24.